PLA2G7
MOLECULAR TARGETphospholipase A2 group VII
PLA2G7 (phospholipase A2 group VII) is targeted by 20 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting PLA2G7
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | darapladib [Supplementary Concept] | 3.00 | 19 |
| 2 | Thyroxine | 1.10 | 2 |
| 3 | myricetin-3-O-galactopyranoside [Supplementary Concept] | 1.10 | 2 |
| 4 | Aripiprazole | 1.10 | 2 |
| 5 | Celecoxib | 1.10 | 2 |
| 6 | Masoprocol | 1.10 | 2 |
| 7 | Perphenazine | 1.10 | 2 |
| 8 | Thyroxine | 1.10 | 2 |
| 9 | Arachidonic Acid | 0.69 | 1 |
| 10 | Tannins Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). | 0.69 | 1 |
| 11 | ag490 | 0.69 | 1 |
| 12 | Aurintricarboxylic Acid | 0.69 | 1 |
| 13 | Calcimycin | 0.69 | 1 |
| 14 | Demeclocycline | 0.69 | 1 |
| 15 | Emodin Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as | 0.69 | 1 |
| 16 | gamma-Linolenic Acid | 0.69 | 1 |
| 17 | Hexachlorophene | 0.69 | 1 |
| 18 | Metergoline | 0.69 | 1 |
| 19 | Oxytetracycline | 0.69 | 1 |
| 20 | Tetracycline | 0.69 | 1 |
About PLA2G7 as a Drug Target
PLA2G7 (phospholipase A2 group VII) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 20 compounds with documented PLA2G7 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
PLA2G7 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.